- Leronlimab is a unique molecule targeting a unique pathway, which gives it strength in numerous indications.
- The company's press doesn't correlate with its value according to the market or other pharmaceutical companies.
- The company's annoying ability of refusing to admit mistakes and manipulating data makes it tough to place a fair value.
- We recommend the company's messaging becomes much clearer and more informative.
- Leronlimab, subject to approval, does have the ability to drive significant shareholder rewards.
For further details see:
CytoDyn Won't Make Your Dreams Come True